BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 18050251)

  • 21. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
    Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
    J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mast cells in bronchoalveolar lavage fluid of patients with interstitial lung diseases].
    Schildge J; Klar B; Hardung-Backes M
    Pneumologie; 2003 Apr; 57(4):202-7. PubMed ID: 12690558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement.
    Vatrella A; Bocchino M; Perna F; Scarpa R; Galati D; Spina S; Pelaia G; Cazzola M; Sanduzzi A
    Respir Med; 2007 Jul; 101(7):1383-9. PubMed ID: 17369033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bronchoalveolar lavage findings in patients with diffuse interstitial lung disease: prospective study of a cohort of 562 patients].
    Jara-Palomares L; Martín-Juan J; Gómez-Izquierdo L; Cayuela-Domínguez A; Rodríguez-Becerra E; Rodríguez-Panadero F
    Arch Bronconeumol; 2009 Mar; 45(3):111-7. PubMed ID: 19286112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
    Behr J; Vogelmeier C; Beinert T; Meurer M; Krombach F; König G; Fruhmann G
    Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):400-6. PubMed ID: 8756813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
    Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M
    Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease.
    Tiev KP; Rivière S; Hua-Huy T; Cabane J; Dinh-Xuan AT
    Nitric Oxide; 2014 Aug; 40():17-21. PubMed ID: 24831352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
    Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
    Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.
    Silver RM; Miller KS; Kinsella MB; Smith EA; Schabel SI
    Am J Med; 1990 May; 88(5):470-6. PubMed ID: 2337105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
    Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
    Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.
    Clements PJ; Goldin JG; Kleerup EC; Furst DE; Elashoff RM; Tashkin DP; Roth MD
    Arthritis Rheum; 2004 Jun; 50(6):1909-17. PubMed ID: 15188367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
    Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
    Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Changes of pulmonary function and partial oxygen pressure before and after bronchoalveolar lavage in patients with interstitial lung diseases].
    Song Y; Li Z; Kang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Oct; 24(10):602-4. PubMed ID: 11770422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bronchoalveolar lavage in interstitial lung diseases: does the recovery rate affect the results?
    Schildge J; Nagel C; Grun C
    Respiration; 2007; 74(5):553-7. PubMed ID: 17496412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstitial lung diseases.
    Rossi G; Andreani A; Morandi P; Marchioni A; Corradini P; Cappiello G; Bortolotti M; Qosja A; Manzini C; Ferri C; Richeldi L; Cavazza A
    Am J Clin Pathol; 2008 Dec; 130(6):927-33. PubMed ID: 19019770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases.
    Vasakova M; Sterclova M; Kolesar L; Slavcev A; Pohunek P; Sulc J; Skibova J; Striz I
    Scand J Immunol; 2009 Mar; 69(3):268-74. PubMed ID: 19281539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pulmonary involvement in sclerodermia].
    Paone G; Di Michele L; Mattia P; Tonnarini R; Lucifora V; Fiorucci F
    Minerva Med; 1994 Jun; 85(6):293-300. PubMed ID: 8084431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.